# Chroma Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chroma-medicine

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.chromamedicine.com
- Total disclosed funding: $236M
- Latest round: Series B (Feb 8, 2023)
- Investors on record: 16

## About

Based in Massachusetts, US, and founded in 2021, Chroma Medicine, Inc. operates as a biotechnology company that deals in a new class of genomic medicines that harness epigenetics. Luke Gilbert, J. Keith Joung, David Liu, Angelo Lombardo, Luigi Naldini, and Jonathan Weissman are the founders of the company. Catherine Stehman-Breen is the CEO of the company as of 2021. In November 2021, Chroma Medicine, Inc. raised USD 125 million in series A funding led by new investor Cormorant Asset Management, with participation from other new investors.

The company is developing a new class of genomic medicines that use epigenetics, nature's fundamental method for gene regulation, to develop novel treatments for patients with genetic illnesses. Its platform enables it to create medications for a wide range of disorders, whether they require gene silencing, activation, or the simultaneous targeting (multiplex editing) of numerous genes.

The company plans to use the proceeds received in the series A funding to support the continued development of the company's epigenetic editing platform and the advancement of its pipeline of targeted therapeutics.

## Funding rounds

- Series B, Feb 8, 2023, $135M — ARCH Venture Partners, Atlas Venture, Sofinnova Partners, T Rowe Price, Alexandria Venture Investments, OUP (Osage University Partners), Wellington Management, GV, Omega Funds, Casdin Capital, DCVC, Cormorant Asset Management, Mubadala Capital, Sixth Street, Janus Henderson Investors, Newpath Partners
- Series A, Nov 17, 2021, $101M — Atlas Venture, Sofinnova Partners, T Rowe Price, Wellington Management, Omega Funds, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners
- Seed, Jun 1, 2020 — Atlas Venture, Sofinnova Partners, Newpath Partners

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series A, Series B
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed, Series A, Series B
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Seed, Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series A, Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series A, Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A, Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A, Series B
- Janus Henderson Investors — Series A, Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series B
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series B
- Sixth Street (https://capitalatlas.ai/funds/sixth-street) — Series B